Lynne A. Murray has a Ph.D. degree from the Imperial College London in immunology and pathology and received postdoctoral training at the UCLA. Following this, Dr. Murray moved into industry and worked at Centocor/Johnson & Johnson in the USA, in chemokine and fibrosis research. Dr. Murray became the Director of Pharmacology at Promedior, a start-up developing therapeutics to treat fibrosis. Now at MedImmune in Cambridge, UK, Dr. Murray is focusing on MedImmune's fibrosis research efforts, both internally and with external collaborators. Dr. Murray's research interests span the underlying pathways promoting the effects of injury, inflammation, and underlying immune conditions on lung remodelling as well as how these mechanisms can translate across multiple organs and disease indications. Dr. Murray has authored multiple papers and book chapters in lung and fibrosis research.
Biography Updated on 9 November 2011